Evidence map›Paper›PMID 16377775›Full record

Trial reportGut2006

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

P Marteau, M Lémann, P Seksik, D Laharie, J F Colombel, Y Bouhnik, G Cadiot, J C Soulé, A Bourreille, E Metman and 9 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 18 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 18 syntheses or guidelines pooled it, 409 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Probiotics for induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2008
    Pooled it
  18. Crohn's disease.BMJ clinical evidence · 2007
    Pooled it
  19. Trial
  20. Trial

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 17 institutions in 3 countries.

P MarteauDépartment Gastroenterology, Hôpital Européen Georges Pompidou, Paris, France. philippe.marteau@lrb.aphp.fr
M Lémann
P Seksik
D Laharie
J F Colombel
Y Bouhnik
G Cadiot
J C Soulé
A Bourreille
E Metman
E Lerebours
F Carbonnel
J L Dupas
M Veyrac
B Coffin
J Moreau
V Abitbol
S Blum-Sperisen
J Y Mary
Institut de Biologie et de Chimie des Protéines · FRESPCI Paris · FRGlaxoSmithKline (United Kingdom) · GBHôpital Armand-Trousseau · FRHôpital Bichat-Claude-Bernard · FRHôpital Charles-Nicolle · FRHôpital Claude Huriez · FRHôpital Européen · FRHôpital Lariboisière · FRHôpital Louis-Mourier · FRHôpital Nord · FRHôpital Robert-Debré · FRHôpital Saint-Louis · FRInserm · FRInteraction Hôtes Agents Pathogènes · FRNestlé (Switzerland) · CHSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsEarly endoscopic recurrence is frequent after intestinal resection for Crohn's disease. Bacteria are involved, and probiotics may modulate immune responses to the intestinal flora. Here we tested the probiotic strain Lactobacillus johnsonii LA1 in this setting. PATIENTS AND

methodsThis was a randomised, double blind, placebo controlled study. Patients were eligible if they had undergone surgical resection of <1 m, removing all macroscopic lesions within the past 21 days. Patients were randomised to receive two packets per day of lyophilised LA1 (2 x 10(9) cfu) or placebo for six months; no other treatment was allowed. The primary endpoint was endoscopic recurrence at six months, with grade >1 in Rutgeerts' classification or an adapted classification for colonic lesions. Endoscopic score was the maximal grade of ileal and colonic lesions. Analyses were performed primarily on an intent to treat basis.

resultsNinety eight patients were enrolled (48 in the LA1 group). At six months, endoscopic recurrence was observed in 30/47 patients (64%) in the placebo group and in 21/43 (49%) in the LA1 group (p = 0.15). Per protocol analysis confirmed this result. Endoscopic score distribution did not differ significantly between the LA1 and placebo groups. There were four clinical recurrences in the LA1 group and three in the placebo group.

conclusionL johnsonii LA1 (4 x 10(9) cfu/day) did not have a sufficient effect, if any, to prevent endoscopic recurrence of Crohn's disease.

Indexed as

LactobacillusAdultColonoscopyCrohn DiseaseDouble-Blind MethodFemaleHumansMaleProbioticsSecondary PreventionSeverity of Illness IndexTreatment FailureTreatment Outcome

Identifiers

PMID16377775
PMCPMC1856210
OpenAlexW2135433890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.